- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02508974
Prevalence of Hospital Malnutrition in Adult Patients
31. mai 2018 oppdatert av: Prof Renee Blaauw, University of Stellenbosch
Prevalence and Impact of Hospital Malnutrition on Associated Outcomes
Malnutrition of patients on admission to hospitals are estimated to be as high as 60%, although the prevalence varies between countries.
The impact of malnutrition on patient recovery and discharge is severe, with extensive cost implications.
This study aims to assess the prevalence of at risk for malnutrition among adult patients admitted to hospital across 3 countries on the African continent.
Studieoversikt
Status
Fullført
Forhold
Detaljert beskrivelse
The prevalence of malnutrition on admission to hospital varies between 15-60%.
Knowing the extent of the problem and identifying at-risk patients should be a priority task since malnutrition is associated with increased hospital-related complications; longer length of stay, increased costs related to treatment and higher mortality.
Post discharge, malnourished patients have also been linked to more frequent re-admissions, higher morbidity and mortality.
Various screening tools are available, including the Nutrition Risk Screening-2002 recommended by European Society for Clinical Nutrition and Metabolism as the preferred screening tool for malnutrition in hospitals in Europe.
ASPEN recommends a more comprehensive evaluation and diagnosis procedure.
In South Africa, and the rest of Africa, nutritional screening is not routinely done and the investigators do not have any reliable national statistics indicating the extent of the problem.
The aim of this study is to determine the prevalence of malnutrition on admission to hospital and to identify the impact thereof on relevant outcomes.
Two different internationally recognised tools will be used and validated for the African context.
In this multi-country, multi-centre descriptive cross-sectional study 3 hospitals in South Africa, 1 in Ghana and 2 in Kenya will be included.
Adult patients (n=400 per hospital) will be screened on admission and at discharge and relevant outcomes (in-hospital and 3-month post-discharge) will be charted.
A 50% sub-sample will be used to validate the 2 instruments.
Studietype
Observasjonsmessig
Registrering (Faktiske)
2126
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Western Cape
-
Cape Town, Western Cape, Sør-Afrika
- Tygerberg Hospital
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Sannsynlighetsprøve
Studiepopulasjon
All adult patients admitted to the hospitals (3 in South Africa [Tygerberg Academic Hospital, Cape Town; Grootte Schuur Academic Hospital, Cape Town; Chris Hani Baragwanath Hospital, Johannesburg]; 2 in Kenya [Aga Khan University Hospital, Nairobi; Mbagathi district hospital, Nairobi] and 1 in Ghana [Korle Bu Teaching Hospital, Accra]) during the defined study periods will be eligible for inclusion in the study.
Beskrivelse
Inclusion Criteria:
- All patients older than 18 years of age
- Males and females
- Admitted to hospital within the past 48 hours
- Conscious
- Informed consent provided
Exclusion Criteria:
- Paediatric patients younger than 18 years
- Pregnant and lactating females
- Patients admitted to ICU, burns or relevant acute care wards
- Patients admitted to psychiatry or eating disorders units
- Patients on dialysis
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in prevalence of risk for malnutrition during the period of hospitalization
Tidsramme: Baseline; day 28
|
Baseline (Admission) data will be gathered during to the first 48 hours after hospital admission.
Discharge data (Day 28) is collected on day of actual discharge or on day 28 of hospitalization if patient is staying in hospital longer than that.
A NRS-2002 score greater than 3 indicates risk for malnutrition.
|
Baseline; day 28
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Association between risk for malnutrition and in-hospital and post-discharge nutritional / medical indicators
Tidsramme: Baseline; day 28 and Day 90
|
Baseline (Admission) data will be gathered during to the first 48 hours after hospital admission.
Discharge data (Day 28) is collected on day of actual discharge or on day 28 of hospitalization if patient is staying in hospital longer than that.
Post discharge data will be gathered 3 months after hospital discharge i.e. day 90 (again within a 48 hour period).
Nutritional indications refer to weight changes (gain or loss) and changes in appetite (improved, no change or decreased).
Medical indicators refer to nr of new complications requiring medical treatment, mortality or re-hospital admission.A NRS-2002 score greater than 3 indicates risk for malnutrition.
|
Baseline; day 28 and Day 90
|
|
Number of patients obtaining similar screening scores as a measure of relative validity of the different screening tools used against each other
Tidsramme: Baseline and day 28
|
Baseline (Admission) data will be gathered during to the first 48 hours after hospital admission.
Discharge data (Day 28) is collected on day of actual discharge or on day 28 of hospitalization if patient is staying in hospital longer than that.
A good validity will be indicated by a sensitivity and specificity of more than 80%.
|
Baseline and day 28
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Renee Blaauw, PhD, University of Stellenbosch
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. januar 2015
Primær fullføring (Faktiske)
1. desember 2017
Studiet fullført (Faktiske)
1. desember 2017
Datoer for studieregistrering
Først innsendt
27. mai 2015
Først innsendt som oppfylte QC-kriteriene
24. juli 2015
Først lagt ut (Anslag)
27. juli 2015
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
1. juni 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
31. mai 2018
Sist bekreftet
1. mai 2018
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- N14/06/061
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .